Institute of Pharmacogenetics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Front Immunol. 2022 Jun 23;13:907343. doi: 10.3389/fimmu.2022.907343. eCollection 2022.
Despite the high level of protection against severe COVID-19 provided by the currently available vaccines some breakthrough infections occur. Until now, there is no information whether a potential risk of a breakthrough infection can be inferred from the level of antibodies after booster vaccination.
Levels of binding antibodies and neutralization capacity after the first, one and six month after the second, and one month after the third (booster) vaccination against COVID-19 were measured in serum samples from 1391 healthcare workers at the University Hospital Essen. Demographics, vaccination scheme, pre-infection antibody titers and neutralization capacity were compared between individuals with and without breakthrough infections.
The risk of developing an Omicron breakthrough infection was independent of vaccination scheme, sex, body mass index, smoking status or pre-existing conditions. In participants with low pre-infection anti-spike antibodies (≤ 2641.0 BAU/ml) and weaker neutralization capacity (≤ 65.9%) against Omicron one month after the booster vaccination the risk for developing an Omicron infection was 10-fold increased ( = 0.001; 95% confidence interval, 2.36 - 47.55).
Routine testing of anti-SARS-CoV-2 IgG antibodies and surrogate virus neutralization can quantify vaccine-induced humoral immune response and may help to identify subjects who are at risk for a breakthrough infection. The establishment of thresholds for SARS-CoV-2 IgG antibody levels identifying "non"-, "low" and "high"-responders may be used as an indication for re-vaccination.
尽管目前可用的疫苗能提供针对严重 COVID-19 的高水平保护,但仍会发生突破性感染。到目前为止,尚不清楚加强接种后抗体水平是否可以推断出突破性感染的潜在风险。
在埃森大学医院,从 1391 名医护人员的血清样本中测量了首次接种、首次接种后 1 个月、第二次接种后 1 个月和第三次(加强)接种后针对 COVID-19 的结合抗体和中和能力水平。比较了有和无突破性感染个体之间的人口统计学特征、疫苗接种方案、感染前抗体滴度和中和能力。
发生奥密克戎突破性感染的风险与疫苗接种方案、性别、体重指数、吸烟状况或既往疾病无关。在加强接种后 1 个月抗刺突抗体(≤2641.0 BAU/ml)和对奥密克戎中和能力(≤65.9%)较低的参与者中,发生奥密克戎感染的风险增加了 10 倍( = 0.001;95%置信区间,2.36-47.55)。
常规检测抗 SARS-CoV-2 IgG 抗体和替代病毒中和能力可以定量疫苗诱导的体液免疫反应,并可能有助于识别有突破性感染风险的个体。建立 SARS-CoV-2 IgG 抗体水平的阈值,以识别“非”、“低”和“高”反应者,可作为重新接种的指征。